| Name | Title | Contact Details |
|---|
Rock & Brews Restaurants is a casual dining chain founded in 2012 by Paul Stanley and Gene Simmons of the band Kiss, along with restaurateur Michael Zislis and partners Dave and Dell Furano. Based in Manhattan Beach, California, the restaurant features a rock-and-roll theme that enhances the dining experience. The menu offers classic American comfort food made from locally sourced ingredients, alongside a selection of craft beers with up to 24 options on tap. Rock & Brews creates a family-friendly atmosphere with amenities like play areas for children and spaces for adults to socialize, all while showcasing rock music videos on LED screens. The brand has expanded to over 23 locations across seven states, including California, Florida, and Texas, and is also present in airports and casinos. Rock & Brews appeals to a diverse customer base, from families to rock music fans, by combining quality food, craft beer, and a lively environment that celebrates the spirit of rock music.
In 2011, KUIU was launched by founder Jason Hairston with the idea of bringing incredible technology and innovation to serious mountain hunters at fair prices. The goal was to fulfill this mission by doing business with uncompromised commitment to quality and consumer transparency. Utilizing a direct to consumer business model, KUIU has brought revolutionary equipment to the hunting industry based off of a technical layering system designed to keep you comfortable and dry in the most extreme hunting conditions. By eliminating the middleman and introducing unmatched technology at unbelievable pricing, KUIU is bringing to life its motto "Innovation Never Rests".
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials such as cathodes, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem is committed to reaching carbon-neutral growth by 2030 and net-zero emissions by 2050 by managing the impacts of climate change and making positive contributions to society through renewable energy and responsible supply chains.